Skip to main content
Log in

Hereditary auto-inflammatory disorders and biologics

  • Original Article
  • Published:
Springer Seminars in Immunopathology Aims and scope Submit manuscript

Abstract

The term auto-inflammatory disorders has been coined to describe a group of conditions characterized by spontaneously relapsing and remitting bouts of systemic inflammation without apparent involvement of antigen-specific T cells or significant production of auto-antibodies. The hereditary periodic fever syndromes are considered as the prototypic auto-inflammatory diseases, and genetic studies have yielded important new insights into innate immunity. DNA analysis has greatly enhanced the clinical characterization of these conditions, and elucidation of their molecular aetiopathogenesis has suggested that therapies may be aimed at specific targets within the immune cascade. The availability of biologic response modifiers such as inhibitors of tumour necrosis factor (TNF) and interleukin-1β has greatly improved the outlook for some of these disorders, although effective therapies remain elusive in patients with certain conditions, including hyperimmunoglobulinaemia-D with periodic fever syndrome (HIDS) and a proportion of those with TNF-receptor associated periodic syndrome (TRAPS). Indeed, outstanding challenges and the unique potential to further elucidate molecular mechanisms in innate immunity are illustrated by the dashed early hope that TNF blockade would be a panacea for TRAPS: not only is etanercept (Enbrel) ineffective in some cases, but there are anecdotal reports of this condition being greatly exacerbated by infliximab (Remicade).

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Aganna E, Martinon F, Hawkins PN et al (2002) Association of mutations in the NALP3/CIAS1/PYPAF1 gene with a broad phenotype including recurrent fever, cold sensitivity, sensorineural deafness, and AA amyloidosis. Arthritis Rheum 46:2445

    Article  PubMed  CAS  Google Scholar 

  2. Aganna E, Hammond L, Hawkins PN et al (2003) Heterogeneity among patients with tumor necrosis factor receptor-associated periodic syndrome phenotypes. Arthritis Rheum 48:2632

    Article  PubMed  CAS  Google Scholar 

  3. Agostini L, Martinon F, Burns K et al (2004) NALP3 forms an IL-l beta-processing inflammasome with increased activity in Muckle–Wells autoinflammatory disorder. Immunity 20:319

    Article  PubMed  CAS  Google Scholar 

  4. Aksentijevich I, Centola M, Deng ZM et al (1997) Ancient missense mutations in a new member of the RoRet gene family are likely to cause familial Mediterranean fever. Cell 90:797

    Article  Google Scholar 

  5. Aksentijevich I, Galon J, Soares M et al (2001) The tumor-necrosis-factor receptor-associated periodic syndrome: new mutations in TNFRSF1A, ancestral origins, genotype–phenotype studies, and evidence for further genetic heterogeneity of periodic fevers. Am J Hum Genet 69:301

    Article  PubMed  CAS  Google Scholar 

  6. Arkwright PD, McDermottt MF, Houten SM et al (2002) Hyper IgD syndrome (HIDS) associated with in vitro evidence of defective monocyte TNFRSF1A shedding and partial response to TNF receptor blockade with etanercept. Clin Exp Immunol 130:484

    Article  PubMed  CAS  Google Scholar 

  7. Arostegui JI, Solis P, Aldea A et al (2005) Etanercept plus colchicine treatment in a child with tumour necrosis factor receptor-associated periodic syndrome abolishes auto-inflammatory episodes without normalising the subclinical acute phase response. Eur J Pediatr 164:13

    Article  PubMed  CAS  Google Scholar 

  8. Ben-Chetrit E, Levy M (1998) Familial Mediterranean fever. Lancet 351:659

    Article  PubMed  CAS  Google Scholar 

  9. Bernot A, Clepet C, Dasilva C et al (1997) A candidate gene for familial Mediterranean fever. Nat Genet 17:25

    Article  Google Scholar 

  10. Bodar EJ, van der Hilst JCH, Drenth JPH et al (2005) Effect of etanercept and anakinra on inflammatory attacks in the hyper-IgD syndrome: introducing a vaccination provocation model. Neth J Med 63:260

    PubMed  CAS  Google Scholar 

  11. Broeders EN, Abramowicz D, Abramowicz MJ et al (2004) A novel mutation of tumor necrosis factor receptor alpha type 1 associated with TRAPS and amyloidosis. Am J Med Genet A 128A:331

    Article  PubMed  Google Scholar 

  12. Calguneri M, Apras S, Ozbalkan Z et al (2004) The efficacy of interferon-alpha in a patient with resistant familial Mediterranean fever complicated by polyarteritis nodosa. Intern Med 43:612

    Article  PubMed  Google Scholar 

  13. Calguneri M, Apras S, Ozbalkan Z et al (2004) The efficacy of continuous interferon alpha administration as an adjunctive agent to colchicine-resistant familial Mediterranean fever patients. Clin Exp Rheumatol 22:S41

    PubMed  CAS  Google Scholar 

  14. de Menthiere CS, Terriere S, Pugnere D et al (2003) INFEVERS: the registry for FMF and hereditary inflammatory disorders mutations. Nucleic Acids Res 31:282

    Article  CAS  Google Scholar 

  15. Deng GM, Zheng LX, Chan FKM et al (2005) Amelioration of inflammatory arthritis by targeting the pre-ligand assembly domain of tumor necrosis factor receptors. Nat Med 11:1066

    Article  PubMed  CAS  Google Scholar 

  16. Derk CT, DeHoratius RJ (2003) Tuberculous tonsillitis in a patient receiving etanercept treatment. Ann Rheum Dis 62:372

    Article  PubMed  CAS  Google Scholar 

  17. di Meglio P, Ianaro A, Ghosh S (2005) Amelioration of acute inflammation by systemic administration of a cell-permeable peptide inhibitor of NF-kappaB activation. Arthritis Rheum 52:951

    Article  PubMed  CAS  Google Scholar 

  18. Diaz A, Hu CB, Kastner DL et al (2004) Lipopolysaccharide-induced expression of multiple alternatively spliced MEFV transcripts in human synovial fibroblasts. Arthritis Rheum 50:3679

    Article  PubMed  CAS  Google Scholar 

  19. Dierselhuis MP, Frenkel J, Wulffraat NM et al (2005) Anakinra for flares of pyogenic arthritis in PAPA syndrome. Rheumatology 44:406

    Article  PubMed  CAS  Google Scholar 

  20. Dinarello CA (1998) Interleukin-1 beta, interleukin-18, and the interleukin-1 beta converting enzyme. In: Molecular mechanisms of fever. Ann N Y Acad Sci 856:1–11

    Article  PubMed  CAS  Google Scholar 

  21. Dode C, Andre M, Bienvenu T et al (2002) The enlarging clinical, genetic, and population spectrum of tumor necrosis factor receptor-associated periodic syndrome. Arthritis Rheum 46:2181

    Article  PubMed  CAS  Google Scholar 

  22. Drenth JPH, Cuisset L, Grateau G et al (1999) Mutations in the gene encoding mevalonate kinase cause hyper-IgD and periodic fever syndrome. Nat Genet 22:178

    Article  PubMed  CAS  Google Scholar 

  23. Drenth JPH, Vonk AG, Simon A et al (2001) Limited efficacy of thalidomide in the treatment of febrile attacks of the hyper-IgD and periodic fever syndrome: a randomized, double-blind, placebo-controlled trial. J Pharmacol Exp Ther 298:1221

    PubMed  CAS  Google Scholar 

  24. Drewe E, Huggins ML, Morgan AG et al (2004) Treatment of renal amyloidosis with etanercept in tumour necrosis factor receptor-associated periodic syndrome. Rheumatology 43:1405

    Article  PubMed  CAS  Google Scholar 

  25. Drewe E, McDermott EM, Powell PT et al (2003) Prospective study of anti-tumour necrosis factor receptor superfamily 1B fusion protein, and case study of anti-tumour necrosis factor receptor superfamily 1A fusion protein, in tumour necrosis factor receptor associated periodic syndrome (TRAPS): clinical and laboratory findings in a series of seven patients. Rheumatology 42:235

    Article  PubMed  CAS  Google Scholar 

  26. Drewe E, McDermott EM, Powell RJ (2000) Treatment of the nephrotic syndrome with etanercept in patients with the tumor necrosis factor receptor-associated periodic syndrome. N Engl J Med 343:1044

    Article  PubMed  CAS  Google Scholar 

  27. Ehrenpreis ED, Kane SV, Cohen LB et al (1999) Thalidomide therapy for patients with refractory Crohn’s disease: an open-label trial. Gastroenterology 117:1271

    Article  PubMed  CAS  Google Scholar 

  28. Eisenberg S, Aksentijevich I, Deng ZM et al (1998) Diagnosis of familial Mediterranean fever by a molecular genetics method. Ann Intern Med 129:539

    PubMed  CAS  Google Scholar 

  29. Frenkel J, Rijkers GT, Mandey SHL et al (2002) Lack of isoprenoid products raises ex vivo interleukin-1 beta secretion in hyperimmunoglobulinemia D and periodic fever syndrome. Arthritis Rheum 46:2794

    Article  PubMed  CAS  Google Scholar 

  30. Frenkel J, Wulffraat NM, Kuis W (2004) Anakinra in mutation-negative NOMID/CINCA syndrome: comment on the articles by Hawkins et al and Hoffman and Patel. Arthritis Rheum 50:3738

    Article  PubMed  Google Scholar 

  31. Galon J, Aksentijevich I, McDermott MF et al (2000) TNFRSF1A mutations and autoinflammatory syndromes. Curr Opin Immunol 12:479

    Article  PubMed  CAS  Google Scholar 

  32. Goldfing SE (1972) Colchicine for familial Mediterranean fever. N Engl J Med 287:1302

    Google Scholar 

  33. Granel B, Serratrice J, Disdier P et al (2005) Dramatic improvement with anakinra in a case of chronic infantile neurological cutaneous and articular (CINCA) syndrome. Rheumatology 44:689

    Article  PubMed  CAS  Google Scholar 

  34. Gumucio DL, Diaz A, Schaner P et al (2002) Fire and ICE: the role of pyrin domain-containing proteins in inflammation and apoptosis. Clin Exp Rheumatol 20:S45

    PubMed  CAS  Google Scholar 

  35. Hamuryudan V, Mat C, Saip S et al (1998) Thalidomide in the treatment of the mucocutaneous lesions of the Behcet syndrome—a randomized, double-blind, placebo-controlled trial. Ann Intern Med 128:443

    PubMed  CAS  Google Scholar 

  36. Hawkins PN, Bybee A, Aganna E et al (2004) Response to anakinra in a de novo case of neonatal-onset multisystem inflammatory disease. Arthritis Rheum 50:2708

    Article  PubMed  Google Scholar 

  37. Hawkins PN, Lachmann HJ, Aganna E et al (2004) Spectrum of clinical features in Muckle–Wells syndrome and response to anakinra. Arthritis Rheum 50:607

    Article  PubMed  CAS  Google Scholar 

  38. Hawkins PN, Lachmann HJ, McDermott MF (2003) Interleukin-1-receptor antagonist in the Muckle–Wells syndrome. N Engl J Med 348:2583

    Article  PubMed  Google Scholar 

  39. He MM, Smith AS, Oslob JD et al (2005) Small-molecule inhibition of TNF-alpha. Science 310:1022

    Article  PubMed  CAS  Google Scholar 

  40. Hoffman HM, Patel DD (2004) Genomic-based therapy: targeting interleukin-1 for autoinflammatory diseases. Arthritis Rheum 50:345

    Article  PubMed  Google Scholar 

  41. Hoffman HM, Rosengren S, Boyle DL et al (2004) Prevention of cold-associated acute inflammation in familial cold autoinflammatory syndrome by interleukin-1 receptor antagonist. Lancet 364:1779

    Article  PubMed  CAS  Google Scholar 

  42. Houten SM, Frenkel J, Rijkers GT et al (2002) Temperature dependence of mutant mevalonate kinase activity as a pathogenic factor in Hyper-IgD and periodic fever syndrome. Hum Mol Genet 11:3115

    Article  PubMed  CAS  Google Scholar 

  43. Houten SM, Kuis W, Duran M et al (1999) Mutations in MVK, encoding mevalonate kinase, cause hyperimmunoglobulinaemia D and periodic fever syndrome. Nat Genet 22:175

    Article  PubMed  CAS  Google Scholar 

  44. Hull KM, Aksentijevich I, Singh H et al (2002) Efficacy of etanercet for the treatment of patients with TNF receptor-associated periodic syndrome (TRAPS). Arthritis Rheum 46:S378

    Article  CAS  Google Scholar 

  45. Hull KM, Kastner DL, Balow JE (2002) Hereditary periodic fever. N Engl J Med 346:1415

    Article  PubMed  Google Scholar 

  46. Hull KM, Wong KD, Wood GM et al (2002) Monocytic fasciitis—a newly recognized clinical feature of tumor necrosis factor receptor dysfunction. Arthritis Rheum 46:2189

    Article  PubMed  CAS  Google Scholar 

  47. Kallinich T, Briese S, Roesler J et al (2004) Two familial cases with tumor necrosis factor receptor-associated periodic syndrome caused, by a non-cysteine mutation (T50M) in the TNFRSF1A gene associated with severe multiorganic amyloidosis. J Rheumatol 31:2519

    PubMed  Google Scholar 

  48. Kary S, Burmester GR (2003) Anakinra: the first interleukin-1 inhibitor in the treatment of rheumatoid arthritis. Int J Clin Pract 57:231

    PubMed  CAS  Google Scholar 

  49. Kastner DL, Aksentijevich I, Galon J et al (1999) TNF receptor associated periodic syndromes (TRAPS): novel TNFR1 mutations and early experience with etanercerpt therapy. Arthritis Rheum 42:S117

    Google Scholar 

  50. Kelley RI (2000) Inborn errors of cholesterol biosynthesis. Adv Pediatr 47:1

    PubMed  CAS  Google Scholar 

  51. Koonin EV, Aravind L (2000) The NACHT family—a new group of predicted NTPases implicated in apoptosis and MHC transcription activation. Trends Biochem Sci 25:223

    Article  PubMed  CAS  Google Scholar 

  52. Lachmann HJ, Sengul B, Yavuzsen TU et al (2006) Clinical and subclinical inflammation in patients with familial Mediterranean fever and in heterozygous carriers of MEFV mutations. Rheumatology. DOI 10.1093/rheumatology/kei279

  53. Lamprecht P, Moosig F, Adam-Klages S et al (2004) Small vessel vasculitis and relapsing panniculitis in tumour necrosis factor receptor associated periodic syndrome (TRAPS). Ann Rheum Dis 63:1518

    Article  PubMed  CAS  Google Scholar 

  54. Lehmann T, Murphy C, Zahra DG et al (2002) Reduction of tumor necrosis factor induced nuclear factor-kappa B nuclear translocation and DNA binding by dexamethasone in human osteoarthritic synovial tissue explants. J Rheumatol 29:787

    PubMed  CAS  Google Scholar 

  55. Levin JI, Chen J, Du M et al (2001) The discovery of anthranilic acid-based MMP inhibitors. Part 2: SAR of the 5-position and P1(1) groups. Bioorg Med Chem Lett 11:2189

    Article  PubMed  CAS  Google Scholar 

  56. Lindor NM, Arsenault TM, Solomon H et al (1997) A new autosomal dominant disorder of pyogenic sterile arthritis, pyoderma gangrenosum, and acne: PAPA syndrome. Mayo Clin Proc 72:611

    Article  PubMed  CAS  Google Scholar 

  57. Lovell DJ, Bowyer SL, Solinger AM (2005) Interleukin-1 blockade by anakinra improves clinical symptoms in patients with neonatal-onset multisystem inflammatory disease. Arthritis Rheum 52:1283

    Article  PubMed  CAS  Google Scholar 

  58. Manadan AM, Block JA, Sequeira W (2003) Mycobacteria tuberculosis peritonitis associated with etanercept therapy. Clin Exp Rheumatol 21:526

    PubMed  CAS  Google Scholar 

  59. Marchetti F, Oretti C, Barbi E et al (2004) Inefficacy of etanercept in a child with hyper-IgD syndrome and periodic fever. Clin Exp Rheumatol 22:791

    PubMed  CAS  Google Scholar 

  60. Martinon F, Burns K, Tschopp J (2002) The inflammasome: a molecular platform triggering activation of inflammatory caspases and processing of proIL-beta. Mol Cell 10:417

    Article  PubMed  CAS  Google Scholar 

  61. Martinon F, Petrilli V, Mayor A et al (2006) Gout-associated uric acid crystals activate the NALP3 inflammasome. Nature advanced online publication

  62. McDermott MF (2004) A common pathway in periodic fever syndromes. Trends Immunol 25:457

    Article  PubMed  CAS  Google Scholar 

  63. McDermott MF (2002) Genetic clues to understanding periodic fevers, and possible therapies. Trends Mol Med 8:550

    Article  PubMed  CAS  Google Scholar 

  64. McDermott MF (2001) TNF and TNFR biology in health and disease. Cell Mol Biol 47:619

    PubMed  CAS  Google Scholar 

  65. McDermott MF, Aksentijevich I, Galon J et al (1999) Germline mutations in the extracellular domains of the 55 kDa TNF receptor, TNFR1, define a family of dominantly inherited autoinflammatory syndromes. Cell 97:133

    Article  PubMed  CAS  Google Scholar 

  66. McDermott MF, Frenkel J (2001) Hereditary periodic fever syndromes. Neth J Med 59:118

    Article  PubMed  CAS  Google Scholar 

  67. Milledge J, Shaw PJ, Mansour A et al (2002) Allogeneic bone marrow transplantation: cure for familial Mediterranean fever. Blood 100:774

    Article  PubMed  CAS  Google Scholar 

  68. Minden K, Aganna E, McDermott MF et al (2004) Tumour necrosis factor receptor associated periodic syndrome (TRAPS) with central nervous system involvement. Ann Rheum Dis 63:1356

    Article  PubMed  CAS  Google Scholar 

  69. Netea MG, Kullberg BJ, Van der Meer JWM (2000) Circulating cytokines as mediators of fever. Clin Infect Dis 31:S178

    Article  PubMed  CAS  Google Scholar 

  70. Neven B, Callebaut I, Prieur AM et al (2004) Molecular basis of the spectral expression of CIAS1 mutations associated with phagocytic cell-mediated autoinflammatory disorders CINCA/NOMID, MWS, and FCU. Blood 103:2809

    Article  PubMed  CAS  Google Scholar 

  71. Nigrovic PA, Sundel RP (2001) Treatment of TRAPS with etanercept: use in pediatrics. Clin Exp Rheumatol 19:484

    PubMed  CAS  Google Scholar 

  72. Obici L, Manno C, Muda AO et al (2004) First report of systemic reactive (AA) amyloidosis in a patient with the hyperimmunoglobulinemia D with periodic fever syndrome. Arthritis Rheum 50:2966

    Article  PubMed  Google Scholar 

  73. Ozgocmen S, Ozcakar L, Ardicoglu O et al (2006) Familial Mediterranean fever responds well to infliximab: single case experience. Clin Rheumatol 25:83

    Article  PubMed  Google Scholar 

  74. Richards N, Schaner P, Diaz A et al (2001) Interaction between pyrin and the apoptotic speck protein (ASC) modulates ASC-induced apoptosis. J Biol Chem 276:39320

    Article  PubMed  CAS  Google Scholar 

  75. Rynne MPMC, Bybee A, McDermott MF, Emery P (2006) Hearing improvement in a variant Muckle–Wells syndrome case in response to interleukin-1 receptor antagonism. Ann Rheum Dis 65:533–534

    Article  PubMed  CAS  Google Scholar 

  76. Seyahi E, Ozdogan H, Masatlioglu S et al (2002) Successful treatment of familial Mediterranean fever attacks with thalidomide in a colchicine resistant patient. Clin Exp Rheumatol 20:S43

    PubMed  CAS  Google Scholar 

  77. Shinkai K, Kilcline C, Connolly MK et al (2005) The pyrin family of fever genes—unmasking genetic determinants of autoinflammatory disease. Arch Dermatol 141:242

    Article  PubMed  CAS  Google Scholar 

  78. Simon A, Bodar EJ, van der Hilst JCH et al (2004) Beneficial response to interleukin I receptor antagonist in traps. Am J Med 117:208

    Article  PubMed  CAS  Google Scholar 

  79. Simon A, Drewe E, van der Meer JWM et al (2004) Simvastatin treatment for inflammatory attacks of the hyperimmunoglobulinemia D and periodic fever syndrome. Clin Pharmacol Ther 75:476

    Article  PubMed  CAS  Google Scholar 

  80. Simon A, van Deuren M, Tighe PJ et al (2001) Genetic analysis as a valuable key to diagnosis and treatment of periodic fever. Arch Intern Med 161:2491

    Article  PubMed  CAS  Google Scholar 

  81. Stack JH, Beaumont K, Larsen PD et al (2005) IL-converting enzyme/caspase-I inhibitor VX-765 blocks the hypersensitive response to an inflammatory stimulus in monocytes from familial cold autoinflammatory syndrome patients. J Immunol 175:2630

    PubMed  CAS  Google Scholar 

  82. Stojanov S, Kastner DL (2005) Familial autoinflammatory diseases: genetics, pathogenesis and treatment. Curr Opin Rheumatol 17:586

    Article  PubMed  CAS  Google Scholar 

  83. Takada K, Aksentijevich I, Mahadevan V et al (2003) Favorable preliminary experience with etanercept in two patients with the hyperimmunoglobulinemia D and periodic fever syndrome. Arthritis Rheum 48:2645

    Article  PubMed  CAS  Google Scholar 

  84. Touitou I (2003) Should patients with FMF undergo BMT? Blood 101:1205

    Article  PubMed  CAS  Google Scholar 

  85. Touitou I, Lesage S, McDermott M et al (2004) Infevers: an evolving mutation database for auto-inflammatory syndromes. Hum Mutat 24:194

    Article  PubMed  CAS  Google Scholar 

  86. Tunca M, Akar S, Soyturk M et al (2004) The effect of interferon alpha administration on acute attacks of familial Mediterranean fever: a double-blind, placebo-controlled trial. Clin Exp Rheumatol 22:S37

    PubMed  CAS  Google Scholar 

  87. Tunca M, Tankurt E, Akpinar HA et al (1997) The efficacy of interferon alpha on colchicine-resistant familial Mediterranean fever attacks: a pilot study. Br J Rheumatol 36:1005

    Article  PubMed  CAS  Google Scholar 

  88. van Duist MM, Albrecht M, Podswiadek M et al (2005) A new CARD15 mutation in Blau syndrome. Eur J Hum Genet 13:742

    Article  PubMed  CAS  Google Scholar 

  89. Vandermeer JWM, Vossen JM, Radl J et al (1984) Hyperimmunoglobulinemia-D and periodic fever—a new syndrome. Lancet 1:1087

    Article  CAS  Google Scholar 

  90. Verity DH, Marr JE, Ohno S et al (1999) Behcet’s disease, the Silk Road and HLA-B51: historical and geographical perspectives. Tissue Antigens 54:213

    Article  PubMed  CAS  Google Scholar 

  91. Weyhreter H, Schwartz M, Kristensen TD et al (2003) A new mutation causing autosomal dominant periodic fever syndrome in a Danish family. J Pediatr 142:191

    Article  PubMed  CAS  Google Scholar 

  92. Williamson LM, Hull D, Mehta R et al (1982) Familial hibernian fever. Q J Med 51:469

    PubMed  CAS  Google Scholar 

  93. Wise CA, Gillum JD, Seidman CE et al (2002) Mutations in CD2BP1 disrupt binding to PTP PEST and are responsible for PAPA syndrome, an autoinflammatory disorder. Hum Mol Genet 11:961

    Article  PubMed  CAS  Google Scholar 

  94. Zemer D, Pras M, Sohar E et al (1986) Colchicine in the prevention and treatment of the amyloidosis of familial Mediterranean fever. N Engl J Med 314:1001

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Michael F. McDermott.

Additional information

Dr. S.M. Churchman and Dr. L.D. Church provided equal contributions to this review.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Church, L.D., Churchman, S.M., Hawkins, P.N. et al. Hereditary auto-inflammatory disorders and biologics. Springer Semin Immun 27, 494–508 (2006). https://doi.org/10.1007/s00281-006-0015-6

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00281-006-0015-6

Keywords

Navigation